By Aphios Corp.
We are currently seeking partners and investors for: Aphios® Pharma LLC is empowering patients with next-generation, extended-release cannabinoid nanoparticles designed to sustainably combat chronic Addiction, Pain, Anxiety, and other debilitating Central Nervous System disorders Amylon™ LLC is developing a novel alpha-secretase modulator, APH-1104, for mild to moderate Alzheimer’s disease and other CNS disorders such as Down’s syndrome and glaucoma. Zindol® LLC is developing Zindol® for chemotherapy-induced nausea and vomiting (CINV), and other nausea/vomiting-induced conditions caused by pregnancy, motion sickness, and drugs. If you are interested in receiving further information, please contact us. We are also seeking partners and investors to further the development and utilization of our enabling technology platforms and enhanced therapeutic products pipeline. We are interested in working with individuals and companies dedicated to improving quality of life, maintaining health and treating unmet medical needs.
